论文部分内容阅读
目的分析胺碘酮联合厄贝沙坦治疗心力衰竭合并心律失常的疗效及其对心功能的影响。方法选取2015年3月至2016年3月心力衰竭合并心律失常患者64例,按随机数表法分为两组,每组32例。对照组实施胺碘酮治疗,观察组在对照组基础上加用厄贝沙坦进行治疗。比较治疗后6个月两组患者心功能指标、疗效及不良反应发生情况。结果治疗后,观察组左心室舒张末期内径、左心室收缩末期内径明显低于对照组,左心室射血分数、每搏心输出量明显高于对照组,差异有统计学意义(P<0.05);观察组治疗效果较对照组明显提高,差异有统计学意义(P<0.05);两组患者不良反应发生率比较差异未见统计学意义(P>0.05)。结论给予心力衰竭合并心律失常患者胺碘酮联合厄贝沙坦治疗,可改善患者心功能,提高治疗效果,且安全性较高。
Objective To analyze the effect of amiodarone combined with irbesartan on heart failure with arrhythmia and its effect on cardiac function. Methods From March 2015 to March 2016, 64 patients with heart failure and arrhythmia were divided into two groups (n = 32 in each group) by random number table. The control group was treated with amiodarone. The observation group was treated with irbesartan on the basis of the control group. Six months after treatment, the cardiac function indexes, curative effects and adverse reactions of the two groups were compared. Results After treatment, left ventricular end-diastolic diameter and left ventricular end-systolic diameter in the observation group were significantly lower than those in the control group. Left ventricular ejection fraction and cardiac output were significantly higher in the observation group than those in the control group (P <0.05) (P <0.05). There was no significant difference between the two groups in the incidence of adverse reactions (P> 0.05). The treatment effect of the observation group was significantly higher than that of the control group, the difference was statistically significant (P <0.05). Conclusion Amiodarone combined with irbesartan in patients with heart failure and arrhythmia can improve cardiac function, improve the therapeutic effect and have higher safety.